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Abstract Transplant rejection is a serious complication, sometimes threatening life of the patient. Although recent 
development of the new generation of immunosuppressive drugs reduced the incidence of acute rejection in kidney 
transplantation, the absence of noninvasive biomarkers of the rejection does not allow often the optimization of a 
prompt antirejection therapy. Serum creatinine is the most widely used marker for allograft function, however, it is not 
sensitive and specific enough to detect acute rejection. Other biomarkers are even less valuable for this purpose. 
Histological examination of renal allograft biopsy still remains the golden standard for diagnosing acute renal allograft 
rejection. Therefore, there is a high demand for reliable biomarkers for noninvasive monitoring of renal allograft status. 
Examination of urine in renal transplant recipients provides a logical and readily accessible approach for this monitoring. 
The high potency biomarkers for kidney allograft monitoring are fragments of DNA in recipient urine that originated 
from renal allograft cells. Because of the difference in the genetic origin these DNA can be distinguished from recipient 
DNA. Quantitative analysis of donor’s DNA, derived from cells of renal allograft, in recipient’s urine might be a reliable 
predictive tool for the kidney transplant rejection. We developed an assay to quantitate donor DNA content in recipient 
urine. Application of the technique—coamplification at lower denaturation temperature-PCR (COLD-PCR) increased the 
abundance of donor DNA that usually presents in recipient urine in quantities that are out of the detection range. This 
assay has a potential for routine application in clinical practice after statistical validation and additional modifications.
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INTRODUCTION
Kidney transplantation is the treatment of choice for most patients 
with end-stage renal disease. About 15,000 kidney transplantations are 
performed per year in USA and assays for monitoring of allograft status 
are highly demanded. Acute rejection is an important risk factor for 
allograft failure [1]. Despite the dramatic improvement in immunological 
matching, surgical techniques and, especially, in the development of 
new immunosuppressive drugs, acute rejection is still a serious medical 
problem among kidney transplant recipients (6-10%). Early diagnosis 
of acute allograft rejection is critical for managing the therapeutic 
approach and for long-term surviving of the transplanted kidney [2].
Typically, renal allograft function is evaluated by measuring serum 
creatinine (SC) levels. Unfortunately, SC level elevation is a non-spe-
cific marker of renal allograft dysfunction, and it may occur in many 
different conditions. Currently, kidney allograft biopsy remains the 
"gold standard" for assessing the cause of kidney transplant dysfunction. 
However, this procedure is damaging, invasive and expensive [3]. The 
alternative for the surgical intervention is a search for novel noninvasive 
biomarkers that will be able to substitute the biopsy, predict clinical 
outcomes, to determine the treatment starting point and regimen and, 
as a result, will improve allograft survival. 
Examination of the urine in renal transplant recipients provides 
a logical and readily accessible non-invasive approach on allograft 
function in its transplanted environment. Renal tubular epithelial cells 
(TEC) respond dynamically to the surrounding microenvironment 
and play an important role in allograft survival. Proteins and DNA 
released from TEC into the urine potentially can serve as biomarkers 
for the early diagnosis of graft dysfunction and rejection. Due to the 
proximity of TEC to the tubular lumen, these proteins, DNA and other 
cell components are passed directly into the urine [4]. Proteomics and 
genomics have been utilized to search for new urine biomarkers for 
early diagnostics and treatment of kidney allograft rejection. Several 
urinary biomarkers (mRNA, miRNA and protein) and especially their 
combination showed some promise in diagnosis of acute renal rejection 
[2, 3, 5]. However, there are limitations in expanding the application of 
these biomarkers from research to clinical practice based on the limited 
statistically relevant data and on the expensive search and complicated 
candidate validation techniques. 
The highly promising alternative to the monitoring specific individ-
ual biomarkers is a cell-free donor DNA in the urine of the transplant 
recipient. It has been shown since the 1950s that ng/ml amounts of 
DNA can be detected in human urine [3]. 
Since the circulating cell-free donor’s DNA in urine of a recipient 
is genetically different from the recipient DNA it might be used for 
molecular diagnostics of renal transplant status. To distinguish the do-
nor’s DNA in urine from DNA derived from host cells it is necessary to 
determine person-specific differences in the sequences of their genomic 
DNA. Several approaches have been already proposed to achieve this 
task. The novel form of chimerism, termed urinary DNA chimerism, 
has been described in kidney transplant recipients. Highly polymorphic 
and individually specific short tandem repeat (STR) loci, were used in 
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this study to detect donor cell-free DNA in recipient urine. Quantitative 
analysis of this DNA in urine has indicated that it may serve as a new 
marker for monitoring kidney transplant status [6]. Another example 
of using urine donor’s DNA as a biomarker for allograft status is the 
detection of donor-specific DNA polymorphism in the urine of the re-
cipient in sex–disparate kidney donor-recipient conditions [7-9]. These 
approaches are restricted by the limited type of donor-recipient pairs. 
Recently the more universal tactic, applicable for any combinations of 
donor-recipient pairs, relied on the new molecular genetic technologies: 
Next Generation Exome Sequencing has been introduced [10]. In this 
study, allograft status was monitored by measuring the amount of donor 
cell-free DNA circulating in the blood of heart transplant recipients. 
Statistically significant increase of donor’s cell-free DNA was observed 
at times when an endomyocardial biopsy independently established 
the presence of acute cellular rejection in heart transplant recipients 
[10]. Although this approach is logical, straightforward and universal, 
it is very expensive, time–consuming and demands special, not easily 
achievable yet, Next Generation Sequencing platforms, software for 
bioinformatics analysis and highly qualified, specially trained personnel. 
The measurement of donor’s DNA in recipient urine is a logical 
approach for renal allograft monitoring. Although it has been shown 
that the amount of donor cell free DNA in recipient urine reflects the 
renal allograft status, the limited statistical significance of these studies, 
insufficient sensitivity of the assays and/or complexity of the approaches 
may hinder the transfer of these techniques to the clinic. 
We propose herein a simple, cost-effective procedure for quantitative 
analysis of donor’s DNA content in the recipient urine, based on the 
predetermined genetic differences in the mitochondrial DNA (mtDNA) 
between the donor and the recipient. Analysis of mtDNA was selected 
because of the known high concentration of single nucleotide poly-
morphism (SNP) in the relatively small area of mtDNA-D-loop [11], 
allowing convenient amplification and sequence analysis. The sequence 
variance in this region for 2 random subjects allows one to distinguish 
mtDNA of donor and recipient mixed in recipient urine. This analysis 
will be applied for monitoring the clinical status of renal allograft. 
The quantitative analysis of donor’s DNA, originated from dying 
cells of renal allograft in recipient urine, will be a reliable predictive 
tool for kidney transplant rejection. The technique includes isolation of 
DNA from urine, modified PCR assays and pyro or Sanger sequencing, 
substituting more expensive and complicated techniques such as Next 
Generation Sequencing, ELISA, qPCR or Luminex. Bioinformatics and 
statistical analysis of these data will be effective and straightforward 
and will not demand special software platforms.
MATERIALS AND METHODS 
Detailed description of the suggested analysis is presented in Figure 1. 
1. Identification of genetic differences by sequencing 
of mtDNA 
To determine the differences in genomic DNA of two random indi-
viduals (donor and recipient) we compared sequences of highly variable 
locus of D-loop in their mitochondrial DNA, which contains more than 
100 SNPs. Based on the results of forensic research, the probability 
of perfect match for these sequences for 2 non-related subjects is low 
(0.5-0.8%) [11]. Consequently, the difference in these sequences (SNPs) 
can be used to distinguish donor and recipient DNA in the urine of a 
renal allograft recipient for the most random pairs. Genomic DNA was 
obtained from related donor and recipient (provided by Tissue Type 
laboratory). All patients gave informed consent to the protocol approved 
by our institutional review board for studies in human subjects. PCR 
amplification of HVR1 and HVR2 region of mtDNA was performed 
with BioRad MJ Mini Thermocycler (BioRad, Hercules, CA) using 
Fast Cycling PCR kit cat# 203741 (Qiagen, Inc Valencia CA) and 
related primers [12]. Primers were ordered from Eurofins MWG Op-
eron (Huntsville, AL). Sequencing was performed with forward PCR 
primer. Sequences were aligned using BLAST software and SNPs that 
are different for donor and recipient were determined.
2. Isolation of cell-free DNA 
DNA from 10 ml of urine was isolated using the Urine DNA isolation 
micro kit (cat# 48800, Norgen Biotek. Corp, Ontario, Canada). Con-
centration of isolated DNA was determined using NanoDrop (Thermo 
Scientific, DE). For every assayed sample we have shown that donor’s 
mtDNA is indeed present in the urine of the renal allograft recipient. 
However, the abundance of donor’s DNA in urine is low. If the total 
cell-free DNA concentration in urine is ranged from 20 to 1000 ng /
ml, the donor’s DNA may be present as 0.1% of the total amount (pg/
ml). This concentration is out of the detection range for conventional 
detection techniques even after PCR amplification.
        
Figure 1. Schema of the proposed procedure. 
3. COLD-PCR 
To increase the proportion of a low abundant allele we have used a 
recently developed technique: COLD-PCR that enables selective am-
plifications of low abundant DNA variants from mixtures of wild-type 
and mutant-containing sequences irrespective of the mutation type or 
position on the amplicon, by using a critical denaturation temperature 
(Tc) [13, 14]. The general outlines of the procedure are described in 
several articles and reviews [13, 14] COLD-PCR can be applied in sev-
eral formats: full-COLD-PCR enriches all types of mutations along the 
sequence, however enrichment is modest (3-10 folds); fast-COLD-PCR 
results to enrichments of 10- to 100-fold, and is robust and time-efficient, 
but is limited to enriching only Tm-reducing mutations (G:C>A:T or 
G:C>T:A [15]. More recently developed platform incorporates a synthetic 
reference sequence within a PCR, designed to enhance amplification 
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of unknown mutant sequences during COLD-PCR. This new platform 
enables an Improved and Complete Enrichment (ice-COLD-PCR) for 
all mutation types and eliminates shortcomings of previous formats 
of COLD-PCR (full- and fast COLD-PCR [15]. Another version of 
COLD-PCR enables simultaneous enrichment of mutations in several 
amplicons and increases significantly the versatility of COLD-PC [16]. 
For the current study we used Full COLD-PCR that is most appli-
cable for any type of mutations. Full COLD-PCR uses a hybridization 
step at an intermediate temperature during PCR cycling to allow 
cross-hybridization of mutant and wild-type alleles. Heteroduplexes, 
which melt at lower temperatures than homoduplexes, are subsequently 
selectively denatured at the Tc and amplified throughout the course 
of the PCR [17]. 
3a. Determination of critical temperature. The first and highly 
important step in the design of the COLD–PCR reaction is determination 
of critical temperature (Tc). The Tc is lower than standard denaturation 
temperatures in that it preferentially denatures heteroduplexed molecules 
(those formed by hybridization of mutant and wild-type sequences) 
and amplicons possessing mutations that lower the amplicon melting 
temperature (Tm), such as G:C>A:T or G:C>T:A [16].
The original presentation of the method suggests several ways 
to determine this parameter: post-PCR real time melting curves 
analysis or theoretical calculation using DNA melting software such 
as MeltSim [18]. To simplify the procedure for the future possible 
clinical application we compared several ways of Tc determination 
and concluded that MeltSim software calculates melting temperature 
of amplicon Tm (the parameter for Tc determination) with high 
accuracy that is adequate to our application [13, 19]. Moreover, to 
further simplify the procedure for clinical application we determined 
that the same Tc can be used in other experimental settings. Minor 
adjustment might be needed for the cases with highly abundant 
mutations. DNA products amplified by COLD-PCR can be directly 
sequenced using Sanger or pyrosequencing. 
3b. Preparation of template DNA. Mixtures of donor/recipient 
mtDNA (1, 2, 5, 10, 20%) will be used as templates for COLD-PCR 
reaction with selected primers and predetermined Tc.
3c. Data collection. Cell-free DNA from patients (recipient) urine 
at different time points will be used for COLD-PCR reactions. Urine 
will be collected during transplant patient visit clinic every 1-2 weeks 
after the surgery and in the hospital if patient will need hospitalization. 
In addition urine will be collected before and after biopsy as often as 
it will be possible. At the same time points SC data will be recorded.
4. Sequencing 
Sanger sequencing currently is the most common procedure for 
determination DNA sequence. Pyrosequencing is an alternative to the 
Sanger sequencing. This method provides several advantages for the 
proposed application; in particular: a. Amplicons after COLD-PCR 
reactions are of the size that is most applicable for pyrosequencing, 
b. Pyrosequencing is much faster procedure than Sanger sequencing 
(results are available in 2 hours)   c. Pyrosequencing is cost-effective.  d. 
Pyrosequencing software allows direct calculation of the proportion of 
2 alleles in the mixture without measuring peak amplitudes. e. The bias 
of this method also can be less than for Sanger sequencing because in 
this method fluorescent-labeled dNTPs are not used. Pyrosequencing of 
COLD-PCR amplicons provides consistent data. However this type of 
sequencing needs more preparative work (primer design). An example 
of pyrosequencing results for COLD-PCR amplicon of cell free DNA 
isolated from urine of transplant recipient is presented in Figure 2.
Figure 2. Pyrosequencing diagram of DNA purified from urine of 
renal transplant patient. Proportion of donor DNA (allele with C nucle-
otide- 35%, with T-65%) is shown. Y-axis: light intensity (relative units).
5. Statistical analysis  
The calculation of the original concentration of low abundant allele 
in recipient urine based on the analysis of sequencing data for COLD-
PCR amplicons is not a straight-forward task. Two major sequencing 
techniques are utilized: Sanger or pyrosequencing (step 4 in Fig. 1). 
When Sanger sequencing is performed, the primary bias source is the 
procedure itself. When the simple approach by measuring fluorescence 
intensity peaks on the sequencing chromatogram was applied for the 
allele frequency calculation of a heterozygote, the expected frequency 
50% was not observed [19]. Possible reasons are different fluorescence 
intensities and the incorporation efficiency for distinct fluorescence-la-
beled dNTPs. In this study the authors solved the problem by including 
heterozygote in the analysis and by using the ratio of two allele-specific 
peak heights of the heterozygote (k) for the correction of the estimated 
mutant frequency. This correction allowed more accurate calculation of 
original mutant concentration in the mixture using modified Equation 1 
[19]. The relative content of donor and recipient DNA is calculated by 
the measuring amplitude of peaks for mutated nucleotide on sequencing 
chromatogram for both alleles. 
Equation 1. Modifications for calculation % of donor DNA in urine. 
Fd-donor allele frequency, Hd-height of the peak of mutated allele, Hr- 
height of the peak of wild allele
We adjusted this equation for our needs. In the current study we 
utilized mtDNA, therefore, instead of using heterozygote for the cor-
rection of the errors, we performed conventional PCR reaction with 
the same primers as for COLD-PCR and as a template the mixture of 
50% recipient/50% donor mtDNA. The ratio of the two peaks on the 
sequencing chromatogram (k) will be used for the correction of the 
calculations in the modified Equation 1. 
Another barrier to the calculation of the original concentration of low 
abundant allele in recipient urine based on the analysis of sequencing 
data of COLD-PCR amplicons is the nature of the COLD-PCR reaction 
since amplification efficiency of low abundant allele by COLD-PCR 
depends of the original concentration of the minor allele in the assay 
mixture and of the chemical composition of the amplicon [20]. 
To establish a reliable procedure for calculation the original amount 
(before amplification) of donor DNA in the recipient urine we first 
*100%
*
HdFd
Hd k Hr
=
+
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performed COLD-PCR-sequencing analysis of serial dilution of donor / 
recipient DNA. An example of the COLD-PCR amplification-sequencing 
results from serially diluted donor/recipient DNA and calibration curve 
based on these data is presented in Figure 3A.  
       
Figure 3. Calibration curve and regression analysis for correction 
of donor DNA measurement in recipient urine. A. Sequencing chro-
matograms of mtDNA mixtures after COLD-PCR reaction. Proportion of 
donor’s DNA is calculated based on the measure of chromatographic peaks 
amplitudes. Blue curve (C)- donor, red curve (T) -recipient. B. Calibration 
plot and segmental regression analysis. 
The results of these calculations are plotted (Fig. 3B). On the Y-co-
ordinate is % of donor DNA calculated by measuring peaks amplitudes 
after COLD-PCR and sequencing and corrections using Equation 1. 
To use this plot as a calibration curve for the calculation of real con-
centration of donor’s DNA in recipient urine we first applied simple 
linear regression analysis. This type of analysis was not adequate for 
the current application. However, segmental linear regression analysis 
provides the basis for the reliable calculation of % of DNA in urine 
based on the sequencing COLD-PCR amplicons using this plot as a 
calibration curve. Segmental regression fits one line to all data points 
with X less than some value X0, and another line to all points with X 
greater than X0, ensuring that the two lines intersect at X0. An exam-
ple of such plot and application of segmental regression analysis is 
presented in Figure 3B. This calibration process is planned for every 
donor/recipient pair. However, since amplicons often are substantially 
similar for different donor-recipient pairs, it is possible that the same 
calibration curve can be used in the future for amplicons with similar 
type of mutations. 
6. Correlation with biopsy results, SC levels and clini-
cal data 
The relative value of donor/recipient cell-free DNA content in the 
recipient urine measured and after correction with calibration curve 
will be plotted over time after transplantation. SC level will be also 
monitored during this period. This factor is routinely assayed for all 
transplant patients. The decision about treatment or renal biopsy is 
generally made based on the elevation of SC over base line for 10-25%. 
Therefore, we suggest that donor DNA elevation in the urine can precede 
SC increase, and can represents a more accurate sign of the potential 
allograft rejection. Since the clinical picture is usually complicated, we 
plan to collect substantial amount of the data and to use comprehensive 
statistical analysis for data interpretation. SAS statistical software will 
be utilized for this analysis. The relationship between urine donor’s 
DNA and SC will be assessed by analysis of variance. A conventional 
receiver operating characteristic (ROC) will be generated for urine do-
nor DNA at the point when it will be increased by 25% to the baseline. 
The area under the curve will be calculated to determine the quality of 
donor DNA as a predictive biomarker for acute rejection. Area of value 
1 will be considered as a perfect biomarker. Positive biopsy will be an 
indicator of true positive. Clinical application statistical analysis will 
be simplified and adjusted for the use with readily available software.
RESULTS
We collected urine from patients that underwent renal transplantation, 
analyzed cell free DNA in these samples and developed the assay for 
quantitation of donor/recipient DNA ratio in urine. Urine was collected 
during every visit of transplant clinic after the surgery. Cell-free DNA 
from urine was isolated and kept frozen, ready for COLD-PCR and 
sequencing. SC data for these time points was documented. SC level 
is usually used as a surrogate marker for allograft status including 
prediction of acute rejection. When SC level increased over 10% we 
performed COLD-PCR and sequencing analysis of the urine samples 
collected for these patients. Once biopsy to examine the allograft 
status was scheduled we obtained all available data (donor DNA level 
in urine) for this patient. Based on these results we can conclude: 1). 
Donor mtDNA can be detected in urine of recipient. 2) This detection is 
possible even for the minimal amount of donor DNA in urine (0.2%) by 
using a modified COLD-PCR technique.  3)  The level of donor DNA 
in urine of renal transplant recipients is a dynamic parameter. 
To explore the possibility of using this parameter for the prediction 
of renal acute rejection we analyzed the kinetics of donor DNA level in 
urine of patients that were scheduled for biopsy because of the increase 
of SC level. One patient was under our observation during 27 weeks 
and was scheduled twice for biopsy; at week 7 and 22. Both times the 
biopsy confirmed acute renal rejection. Another patient was 14 weeks 
under our observation and was scheduled for biopsy at week 5 after 
transplantation. This biopsy did not confirm acute renal rejection (Fig. 
4).  The time course of donor DNA % of total cell–free DNA in recipient 
urine and SC level for the same time points is presented in Figure 4.
 
Figure 4. Time course graphs for % of donor DNA level in urine and 
SC for the same patients. Patient 1 (left panel) had 2 biopsy-confirmed 
acute cellular rejections (indicated by arrows). Patient 2 (right panel) had 
1 biopsy that did not show acute rejection. 
Analysis of these graphs shows that for Patient 1, after the second 
week post-transplantation, SC increased by 30%, which was an indi-
cation of possible rejection. Donor DNA in patient’s urine was also 
increased by 30-35% during which the first biopsy was performed at 
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week 7. After the biopsy level of SC returned to normal, donor DNA 
in the urine continued to increase, possibly because of the allograft 
damage during the biopsy. However, the kinetics of donor DNA level 
in recipient urine not always coincided with the kinetics of SC level. 
Indication for another possible rejection was after week 15 when SC 
levels was increased about 30% and acute rejection was confirmed at 
a later time by biopsy. However, the level of donor DNA in this case 
started rising at week 14, suggesting that this marker can be used for 
earlier prediction of allograft rejection. Patient 2 had an allograft biopsy 
due to a 25% increase in SC after week 4. In this case, biopsy did not 
show acute allograft rejection and donor DNA elevation was not de-
tected during the same time period. Therefore, donor DNA content in 
urine may be a more accurate marker for prediction of acute rejection.
DISCUSSION
In this study we aimed to demonstrate that donor-derived cell-free 
DNA is present in the urine of kidney transplant recipients, and that 
elevated levels of donor DNA can be used as an indication of allograft 
rejection. Analysis of donor DNA in urine may be a more accurate marker 
than those that are currently used. Our data establish unambiguously 
that donor-specific DNA is present in the urine and can be accurately 
quantitated. This quantitation during the time after transplantation 
allows the evaluation of donor DNA content as a noninvasive marker 
for monitoring renal allograft status. 
Currently the assay includes: DNA isolation from genetic mate-
rial of donor and recipient, sequencing and comparison of the target 
sequences. This is a routine procedure for any clinical genetic study 
and can be easily automated. Isolation procedure is reliable and can 
be automated, possible in collaboration with Norgen Biotek, Corp. 
that manufactures urine DNA isolation kits for clinical applications. 
COLD-PCR amplification of cell-free DNA from urine is a relatively 
simple and reliable procedure. As soon as SNPs in D-loop specific for 
donor and recipient are determined COLD-PCR can be performed in any 
clinical laboratory. Quantitative analysis of donor DNA includes several 
simple steps exploiting widely used software. COLD-PCR amplicons 
can be sequenced using primers that were designed for amplification. 
All devices that are necessary for this assay are common in genetically 
oriented clinical laboratories. Sequencing service is also highly available. 
The current study can be considered as a proof of principle that 
elevated level of donor-derived DNA in urine may be a better predic-
tive marker for allograft functions. Additional studies will allow us 
to define the feasibility of the assay and to determine how often urine 
analysis of cell-free DNA must be performed. Considering that the most 
renal allograft rejection events occurred during first 6 month after the 
transplantation, 6-40 urine samples from the patient will be necessary. 
Genetic material for the primary sequencing is already available for 
each pair of donor-recipient. Despite the dramatic improvement in renal 
transplant technology, potential complications must be monitored and 
addressed in a timely fashion.  
Acknowledgments 
We express our appreciation to Dr. Michael Dean, Head of Human Genetics Section 
(National Cancer Institute at Frederick) for fruitful discussion and valuable advices. 
We greatly thank Ann Driscoll from Tissue Type Laboratory, Linda Jackson, Elisha 
Ramos, Lourdes Hartwell, Linda Kurzin and Wendy Devos from Transplantation 
Center for their generosity and highly professional support.
References
1. Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, et al. (2005) 
Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J 
Med 353: 2342-2351. doi: 10.1056/NEJMoa051907. PMID: 16319383 
2. Alachkar N (2012) Serum and urinary biomarkers in acute kidney transplant 
rejection. Nephrol Ther 8: 13-19. doi: 10.1016/j.nephro.2011.07.409. PMID: 
22018843 
3. García Moreira V, Prieto García B, Baltar Martín JM, Ortega Suárez F, Alvarez 
FV (2009) Cell-free DNA as a noninvasive acute rejection marker in renal 
transplantation. Clin Chem 55: 1958-1966. doi: 10.1373/clinchem.2009.129072. 
PMID: 19729469 
4. Ting Y, Coates PT, Walker RJ, McLellan AD (2012) Urinary tubular biomarkers 
as potential early predictors of renal allograft rejection. Nephrology (Carlton) 
17: 11-16. doi: 10.1111/j.1440-1797.2011.01536.x. PMID: 22050577 
5. Alachkar N, Rabb H, Jaar BG (2011) Urinary biomarkers in acute kidney 
transplant dysfunction. Nephron Clin Pract 118: 173-181. doi: 10.1159/000321381. 
PMID: 21160228 
6. Li Y, Hahn D, Zhong XY, Thomson PD, Holzgreve W, et al. (2003) Detection of 
donor-specific DNA polymorphisms in the urine of renal transplant recipients. 
Clin Chem 49: 655-658. doi: 10.1373/49.4.655. PMID: 12651821 
7. Zhong XY, Hahn D, Troeger C, Klemm A, Stein G (2001) Cell-free DNA in 
urine: a marker for kidney graft rejection, but not for prenatal diagnosis. Ann 
N Y Acad Sci 945: 250-257.
8. Zhang Z, Ohkohchi N, Sakurada M, Mizuno Y, Miyagi T, et al. (2001) Diagnosis 
of acute rejection by analysis of urinary DNA of donor origin in renal transplant 
recipients. Transplant Proc 33: 380-381. PMID: 11266871 
9. Sigdel TK, Vitalone MJ, Tran TQ, Dai H, Hsieh S, et al. (2013) A rapid noninvasive 
assay for the detection of renal transplant injury. Transplantation 96: 97-101. 
doi: 10.1097/TP.0b013e318295ee5a. PMID: 23756769 
10. Snyder TM, Khush KK, Valantine HA, Quake SR (2011) Universal noninvasive 
detection of solid organ transplant rejection. Proc Natl Acad Sci U S A 108: 
6229-6234. doi: 10.1073/pnas.1013924108. PMID: 21444804 
11. Kang L, Zhang X, Liu K, Zhao J (2009) [Sequence polymorphisms of the 
mitochondrial DNA HVR I and HVR II regions in the Deng populations from 
Tibet in China]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 26: 690-695. doi: 
10.3760/cma.j.issn.1003-9406.2009.06.018. PMID: 19953496 
12. Köhnemann S, Sibbing U, Pfeiffer H, Hohoff C (2008) A rapid mtDNA assay 
of 22 SNPs in one multiplex reaction increases the power of forensic testing 
in European Caucasians. Int J Legal Med 122: 517-523. doi: 10.1007/s00414-
008-0267-x. PMID: 18712405 
13. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, et al. (2008) Replacing PCR 
with COLD-PCR enriches variant DNA sequences and redefines the sensitivity 
of genetic testing. Nat Med 14: 579-584. doi: 10.1038/nm1708. PMID: 18408729 
14. Castellanos-Rizaldos E, Milbury CA, Guha M, Makrigiorgos GM (2014) COLD-
PCR enriches low-level variant DNA sequences and increases the sensitivity of 
genetic testing. Methods Mol Biol 1102: 623-639. doi: 10.1007/978-1-62703-
727-3_33. PMID: 24259002 
15. Milbury CA, Li J, Makrigiorgos GM (2010) Ice-COLD-PCR enables rapid 
amplification and robust enrichment for low-abundance unknown DNA mutations. 
Nucleic Acids Res 39: doi: 10.1093/nar/gkq899. PMID: 20937629 
16. Castellanos-Rizaldos E, Liu P, Milbury CA, Guha M, Brisci A, et al. (2012) 
Temperature-tolerant COLD-PCR reduces temperature stringency and 
enables robust mutation enrichment. Clin Chem 58: 1130-1138. doi: 10.1373/
clinchem.2012.183095. PMID: 22587896 
17. Milbury CA, Li J, Makrigiorgos GM (2009) COLD-PCR-enhanced high-resolution 
melting enables rapid and selective identification of low-level unknown mutations. 
Clin Chem 55: 2130-2143. doi: 10.1373/clinchem.2009.131029. PMID: 19815609 
18. Dwight Z, Palais R, Wittwer CT (2011) uMELT: prediction of high-resolution 
melting curves and dynamic melting profiles of PCR products in a rich web 
application. Bioinformatics 27: 1019-1020. doi: 10.1093/bioinformatics/btr065. 
PMID: 21300699 
19. Cao P, Wang Q, Zhu X, Zhou H, Li R, et al. (2011) Quantitative determination 
of allele frequency in pooled DNA by using sequencing method. J Chromatogr B 
Analyt Technol Biomed Life Sci 879: 527-532. doi: 10.1016/j.jchromb.2011.01.014. 
PMID: 21277843 
20. Li J, Wang L, Janne PA, Makrigiorgos GM (2009) Coamplification at lower 
denaturation temperature-PCR increases mutation-detection selectivity 
of TaqMan-based real-time PCR. Clin Chem 55: 748-756. doi: 10.1373/
clinchem.2008.113381. PMID: 19233916 
